Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992–2008)
Authors:
- Gillian DankGDGillian Dank
- Kenneth M. RassnickKRKenneth M. Rassnick
- Orna KristalOKOrna Kristal
- Carlos O. RodriguezCRCarlos O. Rodriguez
- Craig A. CliffordCCCraig A. Clifford
- Rebecca WardRWRebecca Ward
- Courtney L. MallettCMCourtney L. Mallett
- Tracy GiegerTGTracy Gieger
- Gilad SegevGSGilad Segev
- 1 October 2011
- journal article
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 239 (7) , 966-971
Abstract
Objective—To determine outcome of dogs with presumed primary hepatic lymphoma treated with various multiagent, doxorubicin-based chemotherapeutic protocols and identify factors associated with prognosis. Design—Retrospective case series. Animals—18 dogs with presumed primary hepatic lymphoma. Procedures—Medical records were reviewed for information on signalment, treatment, and outcome. Results—8 dogs had a complete remission (CR), with a median remission duration of 120 days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or a combination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR. Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariate analysis, response to treatment and serum albumin concentration were associated with MST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs that did achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration < 2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogs with serum albumin concentration within reference limits (10 vs 128 days, respectively). There was also a positive correlation between serum albumin concentration and survival time (r = 0.74). Conclusions and Clinical Relevance—Results suggested that dogs with primary hepatic lymphoma that underwent chemotherapy had a poor prognosis, with a low response rate. Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemia had a poorer prognosis.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy of Combination Chemotherapy for Treatment of Gastrointestinal Lymphoma in DogsJournal of Veterinary Internal Medicine, 2009
- Comparison of 3 Protocols for Treatment after Induction of Remission in Dogs with LymphomaJournal of Veterinary Internal Medicine, 2007
- Comparison of COAP and UW-19 Protocols for Dogs with Multicentric LymphomaJournal of Veterinary Internal Medicine, 2007
- Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004–2005)Journal of the American Veterinary Medical Association, 2007
- Hepatosplenic Lymphoma in a DogVeterinary Pathology, 2003
- Evaluation of a 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2002
- Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine LymphomaJournal of Veterinary Internal Medicine, 2001
- Evaluation of a High-Dose Chemotherapy Protocol with No Maintenance Therapy for Dogs with LymphomaJournal of Veterinary Internal Medicine, 2000
- Evaluation of Prognostic Factors and Sequential Combination Chemotherapy With Doxorubicin for Canine LymphomaJournal of Veterinary Internal Medicine, 1993
- Gastrointestinal Lymphoma in 20 DogsJournal of Veterinary Internal Medicine, 1989